1. Generics Bulletin

BGMA Sets Out Suggestions For VPAS Overhaul

Generics Body Urges Recognition Of Specificities Of The Off-Patent Medicines Market

 
• By Dave Wallace

Claiming that the UK’s VPAS rebate scheme is “out of control,” local generics and biosimilars association the BGMA has set out a series of suggestions to improve the mechanism, as it continues to battle for formal involvement in negotiations with the government.

Two pound coins surrounded by tablets and capsules
VPAS risks making some off-patent medicines unprofitable • Source: Shutterstock

As the British Generic Manufacturers Association continues to pursue legal action seeking a seat at the table as part of UK government negotiations over the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate mechanism, the off-patent industry body has gone public with its proposals, setting out a series of changes that it believes need to be made to reform the “out of control” VPAS scheme.

With the BGMA excluded from full participation in the current negotiations for the new scheme – which will run from 2024 to 2028 – it has made a bid for judicial review of the government’s decision to exclude the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.